Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
Diego Cadavid(Biogen (United States)), Rogier Hintzen(Stanford University), Martin Belkin, Nikos Evangelou(Brigham and Women's Hospital), Olivier Gout(Fondation Ophtalmologique Adolphe de Rothschild), Eduardo Agüera(Hospital Universitario Reina Sofía), Hanka Hertmanowska, Susan M Green(Biogen (United States)), Abdullatif Al Khedr, Victoria Fernández Sánchez, Radek Ampapa(Hospital Jihlava), Steven Freedman, Mira Gavric-Kezic, Óscar Fernández(Universidad de Málaga), Robert Bonek, Ruggero Capra(Presidio Ospedaliero), E. P. Evdoshenko(City Clinical Hospital No 31), Pierre Clavelou(Inserm), Bing Zhu(Biogen (United States)), Yi Chai(Biogen (United States)), Sha Mi(Biogen (United States)), Ih Chang(Biogen (United States)), Wenting Cheng(Biogen (United States)), Peter A. Calabresi(Johns Hopkins University), Hans‐Peter Hartung(The University of Sydney), Keith R. Edwards, Douglas L. Arnold(University of Oxford), Richard A. Rudick(Icahn School of Medicine at Mount Sinai), Aaron Deykin(Biogen (United States)), Jelena Drulović(University of Belgrade), Barry Hendin, Michelle Mellion(Biogen (United States)), Yiwei Zhang(Hubei University of Medicine), Jie Li(Biogen (United States)), Elizabeth Fisher(Novartis (United States)), Lei Xu(Biogen (United States)), Marc Debouverie(Centre Hospitalier Régional et Universitaire de Nancy), Raymond Hupperts(Zuyderland Medisch Centrum), Rafael Arroyo, Gavin Giovannoni(University of British Columbia), Luigi M.E. Grimaldi, Waldemar Fryze, Antonio Garcı́a-Merino, Mark Freedman(Ottawa Hospital), Sarah Sheikh(Biogen (United States)), Alexey Boyко(Pirogov Russian National Research Medical University), Angel Ghezzi, Diego Centonze(University of Rome Tor Vergata)
Cited by 185
Related Papers
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k